9804 MEDICAL CENTER DRIVE, ROCKVILLE, MD
Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; to Receive $100 Million Milestone
Material disclosure
Reports First Quarter 2026 Financial Results and Operational Highlights
Annual Report to Security Holders
Settlement Agreement with GSK - REGENXBIO Inc. to Pay $10 Million
Financial Results, Press Release
Announces Regulatory Update on RGX-121 BLA for MPS II
Announces Regulatory Update on Ultra Rare MPS Programs
Q1
FY 2025
Q3
Q2
FY 2024
SC TO-I
Prospectus filed pursuant to Rule 424(b)(5)
Effectiveness Notice
Registration Statement for Securities Offered under a Shelf Registration
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Definitive Proxy Statement
Additional Proxy Materials
PRE 14A
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Amended Schedule 13G - Ownership Report
Amended Tender Offer Statement by Issuer
Correspondence
Submission Upload
Automatic Shelf Registration Statement